Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 1 August 2026.
Announcements
1,120
Total raised
£24.3B
disclosed amounts
The funding round was led by Octopus Ventures with backing from IP Group and the UCL Technology Fund.
"We believe RRAM has the potential to become the backbone for the next generation of edge and IoT computers at a time when data hungry intelligent applications are becoming more and more prevalent"
Redpoint Ventures led the Series A round, with participation from Balderton Capital and Point Nine, to fund engineering and international growth.
"Attio's mission is to build a CRM that is not only beautiful and intuitive, but powerful enough to empower businesses to scale. That's why we've spent the last three years building a powerful architecture from scratch specifically for CRM,"
The equity portion of the round was led by Iberis Capital, with debt financing from SmartLenders Asset Management.
"The demand for workforce upskilling has never been greater. We’re on a mission to plug this gap across Europe while empowering individuals to level-up their careers. Our platform is currently over-subscribed so, with the new funds, we’re looking forward to helping as many people as possible embark on training courses to upskill. We aim to expand our coverage to build the workforce for the future, in particular in areas such as technology, AI and climate change."
The funding round was co-led by PropTech1 and JLL Spark to expand the hybrid workspace platform internationally.
"We’ve come a long way from launching our initial product from our living rooms in Edinburgh, to working at a global scale with some of the biggest companies in the world as they fundamentally rethink the way they utilise office space. We established Desana ahead of one of the biggest shifts in working culture for generations, and this unprecedented transition has driven a huge amount of growth for us. But, given the scale of the change in this industry, we believe that there’s still so much more to come."
The financing was supported by new investors including InnoSpark alongside returning backers such as the Development Bank of Wales.
"This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators."
.png)
